Evidence map›Paper›PMID 39301906›Full record

ArticleCurrent drug safety2025

Possible Terbinafine and/or Itraconazole Induced Vasculitis - A Case Study.

Sahil Kumar, Swetha Narayanan, Prasan Kumar Panda, Arnab Chowdhury

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Current drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sahil KumarDepartment of Medicine (ID Division), All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Swetha NarayananDepartment of Medicine (ID Division), All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Prasan Kumar PandaDepartment of Medicine (ID Division), All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.ORCID 0000-0002-3008-7245
Arnab ChowdhuryDepartment of Medicine (ID Division), All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIt is essential to exclude other causes, such as autoimmune diseases and bacterial infections, before attributing cutaneous/systemic vasculitis to drug use. CASE STUDY: This report discusses the case of a young man who developed multi-organ failure and cutaneous vasculitis following the use of antifungal medications (terbinafine and itraconazole) for dermatophyte infections. Tests for autoimmune diseases and infections were negative. Given his drug history and a skin biopsy indicating leukocytoclastic vasculitis, it was inferred that the vasculitis was likely drug-induced. Despite treatment with steroids, intravenous immunoglobulins, and plasmapheresis, the patient did not survive, possibly due to delayed diagnosis and treatment.

conclusionIn community practice, Drug-induced Vasculitis (DIV) is frequently overlooked. When patients present with skin rash, fever, and multi-organ dysfunction, DIV should be considered, particularly in the context of recent drug use. Over-the-counter antifungals, like terbinafine or itraconazole, can cause DIV and may be fatal if not promptly diagnosed and treated.

Indexed as

Antifungal AgentsItraconazoleNaphthalenesTerbinafineVasculitisAdultHumansMaleMultiple Organ FailureAntifungal AgentsItraconazoleNaphthalenesTerbinafineAdverse drug reactionantifungalscutaneous vasculitisleukocytoclastic vasculitisover the counter drugs.temporal association

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.